Loading
Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL.
John Seymour was principal investigator of MURANO, the trial showing two years of venetoclax plus rituximab dramatically improves progression-free and overall survival compared with bendamustine-rituximab in relapsed CLL, the first randomised proof of venetoclax's benefit and the first fixed-duration targeted regimen. He co-led the first-in-human venetoclax studies with the Melbourne group that discovered BCL2 inhibition and leads haematology at Peter Mac.
Shares BCL-2, CD20, Venetoclax, MRD / molecular residual disease testing and the tags cll, venetoclax.
Shares BCL-2, CD20, Venetoclax, MRD / molecular residual disease testing and the tags cll, venetoclax.
Shares Peter MacCallum Cancer Centre, BCL-2, Venetoclax, MRD / molecular residual disease testing and the tags venetoclax, australia.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tag cll.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia and the tags cll, australia.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tag cll.
Shares BCL-2, CD20, Venetoclax, Chronic lymphocytic leukaemia.
Shares Peter MacCallum Cancer Centre, CD20 and the tag australia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/